Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

This study is testing a combination of two anti-cancer drugs — pazopanib (a targeted therapy) and a metronomic chemotherapy regimen (TGI/CIV, meaning low-dose chemotherapy given frequently) — for children and adolescents with rhabdomyosarcoma (RMS), a rare cancer of the soft tissue, whose cancer has come back or stopped responding to treatment. **You may be eligible if...** - You are between 2 and 18 years old - You have a confirmed diagnosis of rhabdomyosarcoma - Your cancer has relapsed after complete remission, or it did not respond to at least four cycles of first-line chemotherapy - Your cancer is measurable on scans - Your physical performance status is adequate for treatment **You may NOT be eligible if...** - You have serious heart, liver, or kidney problems - You have uncontrolled high blood pressure - You have had certain recent surgeries or other anticancer therapies within required washout periods Talk to your doctor to see if this trial is right for you.